Navigation Links
Oclaro Announces Second Quarter Fiscal Year 2013 Financial Results
Date:1/31/2013

SAN JOSE, Calif., Jan. 31, 2013 /PRNewswire/ -- Oclaro, Inc. (NASDAQ: OCLR), a provider of optical components, modules and subsystems, today announced the financial results for its second quarter of fiscal year 2013, which ended December 29, 2012.

"Our financial results for the second quarter of fiscal 2013 demonstrate the progress we are making after the merger," said Alain Couder, chairman and CEO. "Our revenues were at the top-end of guidance and we have successfully executed to the planned synergies on schedule. We also took action to strengthen our balance sheet.  Looking ahead, market and economic conditions remain uncertain in a typically softer March quarter. As a result, our efforts will remain focused on reducing operating expenses and improving margin, as well as capitalizing on our new product introductions and strong customer relationships to maximize revenues."

Results for the Second Quarter of Fiscal 2013:Oclaro closed its merger with Opnext, Inc. on July 23, 2012. The financial results for the second quarter of fiscal 2013 include a full quarter of operating results of Opnext. The financial results for the first quarter of fiscal 2013 include approximately ten weeks of operating results of Opnext since the closing of the merger. Results for the second quarter of fiscal 2012 were pre-merger Oclaro and do not include the operating results of Opnext.

  • Revenues were $159.5 million for the second quarter of fiscal 2013, compared with revenues of $148.8 million in the first quarter of fiscal 2013. Pro forma combined revenues for the first quarter of fiscal 2013, including Opnext for the full quarter, were $160.2 million.
  • GAAP gross margin was 13% for the second quarter of fiscal 2013, compared with a GAAP gross margin of 12% in the first quarter of fiscal 2013.
  • Non-GAAP gross margin was 15% for the second quarter of fisca
    '/>"/>

  • SOURCE Oclaro, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. Oclaro Announces Fourth Quarter and Fiscal Year 2012 Financial Results
    2. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
    3. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
    4. Blue Belt Technologies Announces First U.S. Sale of NavioPFS Surgical System
    5. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
    6. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
    7. Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
    8. Kemwell Announces Successful Pre-NDA US FDA Inspection
    9. Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
    10. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
    11. Vanish Announces Tattoo Removal Giveaway for Valentines Day
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... , Oct. 22, 2014 Provectus Biopharmaceuticals, Inc. ... PV-10, its novel investigational drug for cancer, is designed ... systemic side effects. Its oncology focus is on melanoma, ... completed phase 2 trials of PV-10 as a therapy ... treatment for atopic dermatitis and psoriasis. ...
    (Date:10/22/2014)...  Recently published clinical studies of Stretta for gastroesophageal ... of evidence. This data has led to significantly expanded ... for sufferers of refractory GERD. The ... therapy as a safe and effective GERD treatment has ... to nearly 50 million Americans. The new clinical studies ...
    (Date:10/22/2014)... Mass. and SHANGHAI , ... (NASDAQ: FMI ) and WuXi PharmaTech ... a collaboration to offer Foundation Medicine,s comprehensive genomic profiling ... China . Under the terms ... WuXi to perform the laboratory component of Foundation Medicine,s ...
    Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5
    (Date:10/22/2014)... Norton HealthDay Reporter , TUESDAY, ... the three Ebola cases in Dallas. But, mental health specialists ... Americans. President Barack Obama on Friday appointed an Ebola ... has infected two Dallas nurses who cared for a Liberian ... Presbyterian Hospital. But the U.S. cases are miniscule in ...
    (Date:10/22/2014)... October 22, 2014 With the Affordable Care ... survey by the American Institutes for Research (AIR) finds that ... to use health insurance, but 42 percent say they are ... details before signing up for coverage. , The AIR survey ... 20 percent able to calculate correctly how much they owe ...
    (Date:10/22/2014)... Although there are only 24 hours in a ... who have trouble finding time within their busy schedules for exercise ... periods of time to get in shape. Here are five ways ... go. , Change Up Your Commute , Consider riding a ... some exercise into your daily routine. If you must use your ...
    (Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... women undergoing in vitro fertilization (IVF) are only about half ... popular assisted reproduction technique, new research indicates, and the racial ... the study, about 31 percent of white patients became pregnant ... Analyzing more than 4,000 IVF cycles over two years ...
    (Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... health officials on Monday officially tightened guidelines for health workers ... skin exposure and use of a respirator at all times. ... to issue the tougher rules after two Dallas nurses contracted ... the United States, Liberian national Thomas Eric Duncan. Nina Pham ...
    Breaking Medicine News(10 mins):Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
    ... microscope, scientists have tried to visualize smaller and smaller structures ... bacteria and viruses. Now, researchers at the National Institute ... the National Institutes of Health, have developed a new way ... before. Their findings are reported in the Jan. 13 ...
    ... (HealthDay News) -- The chemotherapy used to treat a form ... the return of the disease within years, a new study ... who thought chemotherapy drugs could disrupt DNA through mutations and ... medications. "Chemotherapy drugs are absolutely necessary to get ...
    ... Jefferson,s Kimmel Cancer Center has started a ... cancer chemotherapy drug to extend survival, Cabazitaxel, in ... approach could improve disease control and eventually survival ... single-center, open-label, non-randomized Phase I study ...
    ... Using two cell surface markers found to be ... researchers at Moffitt Cancer Center, working with colleagues ... imaging probes that can non-invasively detect breast cancer ... breast cancer patients invasive and unreliable sentinel lymph ...
    ... women are scarce leads men to become impulsive, save less, ... of Minnesota,s Carlson School of Management. "What we see ... become more competitive. They compete more for access to mates," ... Carlson School and lead author of the study. "How do ...
    ... language are quicker at recognizing and interpreting body language than ... Davis and UC Irvine. The work suggests that deaf ... visual traits in the actions of others, an ability that ... screening. "There are a lot of anecdotes about deaf ...
    Cached Medicine News:Health News:NIH scientists identify novel approach to view inner workings of viruses 2Health News:DNA Damage From Chemo May Help Spur Leukemia's Return 2Health News:Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival 2Health News:Researchers find new, noninvasive way to identify lymph node metastasis 2Health News:A scarcity of women leads men to spend more, save less 2Health News:A scarcity of women leads men to spend more, save less 3Health News:Deaf sign language users pick up faster on body language 2
    Solid 14 mm free-swinging blades, suture posts, and stabilizing disk. Dull finish....
    Fenestrated 14 mm blades and canthus bar. Adjustable blade locking screws on outside of branches. Dull finish....
    Double bent ends prevent wire from catching when pushed forward. Designed for use with the Castroviejo Snare (E3675). Package of 12 stainless steel wires. Overall length 4.3 inches....
    Replacement snares for the E3525. 3 per package....
    Medicine Products: